NCT05863845View on ClinicalTrials.gov

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

NANot yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Venetoclax

100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO

DRUG

Carmustine

300mg/m2 day -7, Given IV

DRUG

Cytarabine

100mg/m2/d, day -6 to day -3, Given IV

DRUG

Etoposide

200mg/m2/d, day -6 to day -3, Given IV

DRUG

Melphalan

140mg/m2, day -2, Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo hematopoietic cell transplantation

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT05863845 - Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | Biotech Hunter | Biotech Hunter